Sun Pharmaceutical Industries Ltd
SUN.BO- Latest Trade
- trading lower902.8INR
- Change
- -8.35
- % Change
0.92%Negative
- Day Range
- 895.30 - 922.00
- 52-Week Range
- 652.75 - 966.90
As of May 26 2022. Values delayed up to 15 minutes
- Previous Close
- 911.15
- Open
- 919.00
- Volume
- 90,715.00
- 3 Month Average Trading Volume
- 58.74
- Shares Out (Mil)
- 2,399.33
- Market Cap
- 2,183,155.00
- Forward P/E
- 28.99
- Dividend Yield
- 0.99
Key Statistics
1.68421053 mean rating - 38 analysts
- P/E Excl. Extra Items (TTM)
- 33.92
- Price To Sales (TTM)
- 5.79
- Price To Book (Quarterly)
- -99,999.99
- Price To Cash Flow (Per Share TTM)
- 25.34
- Total Debt/Total Equity (Quarterly)
- -99,999.99
- Long Term Debt/Equity (Quarterly)
- -99,999.99
- Return On Investment (TTM)
- -99,999.99
- Return On Equity (TTM)
- -99,999.99
2021 (millions USD)
About Sun Pharmaceutical Industries Ltd
Company Information
Sun Pharmaceutical Industries Limited is a specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a range of generic formulations. It produces a portfolio of generic and specialty medicines targeting a spectrum of chronic and acute treatments. The Company’s product portfolio includes generics, branded generics, specialty, over the counter (OTC)/consumer healthcare products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates. Its OTC brands includes Faringosept , Revital, and Volini. The Company offers its products in variety of dosage forms, such as tablets, capsules, sprays, injectables, inhalers, ointments, creams and liquids. Its portfolio of specialty products, branded generics are available across 100 countries. The Company operates manufacturing sites across 6 continents.
Address
Sun House, CTS No. 201 B/1,, Western ExpMUMBAI,
400063
India
Industry
Biotechnology & Drugs
Executive Leadership
- Israel Makov
- Non-Executive Chairman of the Board
- C. S. Muralidharan
- Chief Financial Officer
- Uday Baldota
- Chief Executive Officer - Taro Pharmaceutical Industries Limited
- Abhay Gandhi
- Chief Executive Officer, North America
- Kirti Ganorkar
- Chief Executive Officer - India Business
- Anilkumar Jain
- Chief Executive Officer - API Business
- Jila Breeze
- Executive Vice President, Global Head - Quality
- Pradeep Sanghvi
- Executive Vice President, Head - Research and Development, US
- Aalok Dilip Shanghvi
- Executive Vice President, Head - Emerging Markets, Head - Global Generics, Research and Development, Business Development
- Davinder Singh
- Executive Vice President - Sun Global Operations
- Sapna Purohit
- Senior Vice President, Head of Human Resources
- Azadar H. Khan
- Senior Vice President - Corporate Relations and Corporate Social Responsibility, India Regulatory Affairs
- Sreenivas Rao
- Senior Vice President, Head - Global Supply Chain
- Anoop Deshpande
- Compliance Officer, Company Secretary
- Dilip Shantilal Shanghvi
- Managing Director, Executive Director
- Sailesh T. Desai
- Whole-Time Director
- Subramanian Kalyanasundaram
- Whole-time Director, Director - Corporate Development
- Kalyanasundaram Subramanian
- Whole-Time Director
- Hellen De Kloet
- Business Head, Western Europe, Australia and New Zealand
- Sudhir Vrundavandas Valia
- Non-Executive Director
- Rama Bijapurkar
- Additional Independent Director
- Pawan Kumar Goenka
- Additional Independent Director
- Gautam Bhailal Doshi
- Non-Executive Independent Director
- Rekha Sethi
- Non-Executive Independent Director
Markets Performance
Official Data PartnerCommodities
Future | Last | % Change |
---|---|---|
Gold | 1,846.20 | -- |
Copper | 774.40 | 0.70%Negative |
Brent Crude Oil | 114.70 | 0.59%Positive |
CBOT Soybeans | 1,680.50 | 0.03%Negative |
Stocks
Index | Last | % Change |
---|---|---|
S&P 500 | 3,978.73 | 0.95%Positive |
Euro STOXX 50 | 3,695.25 | 0.49%Positive |
FTSE 100 | 7,533.16 | 0.14%Positive |
Nikkei 225 | 26,604.84 | 0.27%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes